Why Aurinia Pharmaceuticals Is Soaring Today
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH), a clinical-stage biopharmaceutical company focused on rare diseases, were up 10% as of 11:05 a.m. EDT on Tuesday after management issued a press release that contained upbeat clinical and financial news.
Management wanted to get three main points across to investors today.
First, its last patient study visit has occurred in its phase 3 AURORA program. This trial is studying its lead compound, voclosporin, as a hopeful treatment for lupus nephritis. Efficacy and safety data from the trial are on track to be shared with investors before the end of the year.
Source Fool.com
